首页|Coverage and Pricing Recommendations of the French National Health Authority for Innovative Drugs: A Retrospective Analysis From 2014 to 2020

Coverage and Pricing Recommendations of the French National Health Authority for Innovative Drugs: A Retrospective Analysis From 2014 to 2020

扫码查看
原文链接
  • NSTL
  • Elsevier
Objectives: This study provides a retrospective analysis of the recommendations of the French National Health Authority on the reimbursement and pricing of innovative drugs. Methods: The analysis includes drugs subjected to both economic and clinical evaluations in France from 2014 to 2020. Ordered logistic and quantile regressions are used to estimate the factors associated with the clinical value (SMR), the clinical added value (ASMR), and the incremental cost-utility ratio (ICUR) of innovative drugs. All variables used in the regression analyses are extracted from the Clinical and Economic Opinions for the 146 observations. Results: Regression analyses indicate that 2 of the 5 official criteria, the efficacy-adverse events balance of the drug and its function, are significantly associated with the SMR rating. The ASMR is positively associated with the disease severity, the quality-adjusted life-year (QALY) gain provided by the drug, and the validation of the ICUR in the Economic Opinion. At the first quartile of the ICUR distribution (approximately euro 50 000/QALY), higher ICUR levels are observed for drugs with a smaller target population and for drugs claimed as more innovative. Higher ICUR levels are also observed for pediatric drugs and for drugs with no therapeutic alternative at the third quartile of the distribution (approximately euro 240 000/QALY). Conclusions: Not all official criteria of the SMR are associated with actual ratings obtained. Regarding the ASMR, the results support the idea of a convergence between the 2 independent clinical and economic appraisal processes. Finally, the factors influencing the ICUR level vary across the distribution of ICUR.

clinical added valueclinical benefitdrug pricingeconomic evaluationFrancehealth technology assessmentincremental cost-utility ratioreimbursementSURROGATE END-POINTSTECHNOLOGY-ASSESSMENTDISEASE SEVERITYDECISION-MAKINGREIMBURSEMENTPREFERENCESCAREAUSTRALIASURVIVALCRITERIA

Kergall, Pauline、Autin, Erwan、Guillon, Marlene、Clement, Valerie

展开 >

Univ Montpellier

French Natl Hlth Author

2021

10.1016/j.jval.2021.06.013

Value in health

Value in health

SCI
ISSN：1098-3015
年,卷(期)：2021.24(12)
  • 36